https://www.fiercepharma.com/pharma/asco-merck-details-keytruda-s-second-stomach-cancer-slip
https://www.evaluate.com/vantage/articles/events/conferences/asco-2019-top-marks-effort-merck-co-gastric-cancer
Merck's second stomach cancer slip could turn out to be quite auspicious for us, as they now have to go back to the drawing board and design a new trial. Interestingly, Dr. Josep Tabernero was the trial's lead investigator and has also been a consultant to Merck in the past. I think it's safe to assume that Dr Josep Tabernero has the eyes and ears of Merck's people.
From the below photo (November 2018), we know that we already have made contact with Merck's people.
Interesting times ahead.
https://www.facebook.com/Imugene/photos/a.572970402723551/2148644111822831/?type=3&theater
ASCO Conference, page-25
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.5¢ |
Change
0.002(4.65%) |
Mkt cap ! $334.7M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.5¢ | 4.3¢ | $732.0K | 16.76M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1799587 | 4.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 1003772 | 13 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |